TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25380842
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Group E: RF therapy)
Study: 25380842
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Group F: common metal stent implantation)
Study: 22008715
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with SLA surface
Study: 15784070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nicotine and smoking-related stimuli
Study: 8687199
Drug: Lazabemide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 25 mg/day
Study: 8687199
Drug: Lazabemide 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 50 mg/day
Study: 12359039
Drug: Lazabemide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 100 mg/day
Study: 12359039
Drug: Lazabemide 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 200 mg/day
Study: 1531994
Drug: Budesonide, 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 1.6 mg daily for 3 weeks
Study: 1531994
Drug: Prednisone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 40 mg daily for 8 days
Study: 4072589
Drug: N2O, oxygen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2O, oxygen, and halogenated agents
Study: 31623675
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C supplementation (500 mg daily during the last 2 cycles)
Study: 24362951
Drug: Everolimus (EVE)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVE) + Exemestane (EXE) (10 mg/day + 25 mg/day)
Study: 24362951
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) + Exemestane (EXE) (placebo + 25 mg/day)
Study: 20211040
Drug: Maternal multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal multivitamin supplements
Study: 12356611
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine combined with interferon alfa
Study: 8540719
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily for 6 days)
Study: 8540719
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg every 8 h for 5 days plus omeprazole)
Study: 31669837
Drug: Saffron (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (60 mg/day)
Study: 25765348
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil topical foam (5% MTF)
Study: 26387973
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical foam (plaTF) until week 24, followed by 5% MTF until week 104
Study: 23052313
Drug: Trimethoprim-sulfamethoxazole (SXT)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (SXT) on Mueller-Hinton agar (MHA) with defibrinated horse blood and 20 mg/liter β‐NAD (MHF)
Study: 10193219
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg.kg‐1
Study: 9797517
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg.kg‐1
Study: 9797517
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg.kg‐1 with spontaneous recovery
Study: 9797517
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 10% recovery
Study: 9797517
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 25% recovery
Study: 9797517
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg.kg‐1 with spontaneous recovery
Study: 9797517
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 10% recovery
Study: 9797517
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 25% recovery
Study: 9797517
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg.kg‐1 with spontaneous recovery
Study: 9797517
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg.kg‐1 with neostigmine at 10% recovery
Study: 9797517
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg.kg‐1 with neostigmine at 25% recovery
Study: 241599
Drug: Alclofenac 1
Normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclofenac 1 g t.d.s.
Study: 17114560
Drug: Midazolam syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup (0.5 mg/kg)
Study: 9235377
Drug: Ozone-containing solutions
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone-containing solutions
Study: 8234438
Drug: Bulk laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk laxative plus senna (Agiolax) daily doses 14.8 g
Study: 8234438
Drug: Lactulose (Levolac)
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose (Levolac) daily doses 20.1 g
Study: 3303178
Drug: 1% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mepivacaine (40 ml)
Study: 3303178
Drug: 1% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prilocaine (40 ml)
Study: 23559323
Drug: Postoperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative systemic steroids (100 mg prednisolone per day for 5 days)
Study: 15572391
Drug: Knee pain
Normalized name: Tenscare Kneestim For Knee Pain And Arthritis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee pain induced by injection of hypertonic saline into the infrapatellar fat pad
Study: 8862101
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 to 40 mg once daily
Study: 6131914
Drug: anti-H1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-H1 plus anti-H2 (cimetidine, 300 mg t.i.d.)
Study: 28449710
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (HES) 130/0.4, 20 mL·kg‐1
Study: 28449710
Drug: 5% Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Human Albumin (HA), 20 mL·kg‐1
Study: 23765203
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of dietary MSG and aspartame (n = 36)
Study: 12585189
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo capsule (TXLC)
Study: 2148882
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Study: 2148882
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Study: 2148882
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GM-CSF (0.3-30 micrograms/kg)
Study: 2148882
Drug: All methods
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All methods of administration (subcutaneous bolus, intravenous bolus, intravenous infusion)
Study: 2148882
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of GM-CSF at doses below 3 micrograms/kg
Study: 2148882
Drug: All methods
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All methods of administration
Study: 106264
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 50 mg bezafibrate daily
Study: 106264
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 100 mg bezafibrate daily
Study: 106264
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 150 mg bezafibrate daily
Study: 106264
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 200 mg bezafibrate daily
Study: 106264
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg bezafibrate daily (optimal dose)
Study: 30563932
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg daily for 3 days, then twice daily for 1 to 5 weeks)
Study: 19479614
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiotherapy (RT) after induction chemotherapy (CT)
Study: 12577415
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) alone
Study: 11485506
Drug: Alosetron hydrochloride
Normalized name: Alosetron Hydrochloride
DrugBank: Alosetron (DB00969)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alosetron hydrochloride 1 mg twice daily for 12 weeks
Study: 2692178
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol 4 mg t.d.s.
Study: 2692178
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol infused until maternal heart rate rose above 100 bpm for 30 mins
Study: 31427745
Drug: TIMOLOL nasal
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TIMOLOL nasal spray (0.5%) administered as one spray (50 µL) in each nostril twice a day for 28 consecutive days.
Study: 31427745
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray administered as one spray (50 µL) in each nostril twice a day for 28 consecutive days.
Study: 27889661
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with PSA threshold of 3 ng/ml
Study: 27889661
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with PSA threshold of 4 ng/ml
Study: 26272447
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy with lavender oil (2 consecutive cycles of effleurage massage)
Study: 24156091
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement taken each dialysis session (drink or pudding style)
Study: 22205554
Drug: MCT/LCT fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT/LCT fat infusion
Study: 22205554
Drug: Fish oil‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil‐based (ω‐3) fat infusion
Study: 16918949
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (1.3, 2.0 and 2.7 mg/m2/day)
Study: 16918949
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (2.7 mg/m2/day)
Study: 12950901
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg twice a day for 2 days (days 1 and 2)
Study: 12950901
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg twice a day for 8 days (days 1 and 8)
Study: 12950901
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg single dose (day 1)
Study: 10872186
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (children without rhGH treatment)
Study: 9166391
Drug: Ipriflavone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (200 mg t.i.d)
Study: 4074623
Drug: +sotalol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: +sotalol (0.125 mg kg‐1 to 2.0 mg kg‐1)
Study: 21969017
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control)
Study: 23865441
Drug: LOS +
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LOS + HCTZ (50 mg/day losartan + 12.5 mg/day hydrochlorothiazide)
Study: 23865441
Drug: TEL +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEL + HCTZ (40 mg/day telmisartan + 12.5 mg/day hydrochlorothiazide)
Study: 7846193
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean dose 75 mg daily) plus mianserin (mean dose 25 mg daily)
Study: 7846193
Drug: Desipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (mean dose 66 mg daily) plus mianserin (mean dose 27 mg daily)
Study: 31172644
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg oral administration)
Study: 29103416
Drug: Phlai capsules
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlai capsules 100 mg
Study: 29103416
Drug: Phlai capsules
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlai capsules 200 mg
Study: 25882986
Drug: Pazopanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib plus weekly paclitaxel (800 mg daily + 80 mg/m² weekly)
Study: 25882986
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel alone (80 mg/m² weekly)
Study: 25882986
Drug: Pazopanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib plus weekly paclitaxel
Study: 22813409
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol (60,000 units/week) and calcium carbonate (1g/day) along with anti-tubercular treatment (ATT)
Study: 16395307
Drug: Naltrexone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 25 mg pretreatment with lower subperceptual ketamine dose (0.081 mg/kg bolus, 0.4 mg/kg/h infusion)
Study: 16395307
Drug: Higher perception-altering
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher perception-altering ketamine dose (0.23 mg/kg bolus, 0.58 mg/kg infusion)
Study: 16395307
Drug: Lower subperceptual
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower subperceptual ketamine dose
Study: 16395307
Drug: Higher ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher ketamine dose
Study: 19222770
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Study: 19222770
Drug: Preoperative saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative saline and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Study: 16508385
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 4 days before surgery and oral rofecoxib 50 mg on the morning of surgery
Study: 16508385
Drug: Oral rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rofecoxib 50 mg for 4 days before surgery and the morning of surgery
Study: 11524352
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (15 mL, 75 mg)
Study: 9236446
Drug: Vehicle (air)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (air) inhalation
Study: 8103703
Drug: Cetirizine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (15 mg twice daily for 1 week)
Study: 8103703
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after single dose PAF challenge)
Study: 8103703
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after 1 week treatment)
Study: 3092699
Drug: 0.15‐0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15‐0.2 mg/kg nalbuphine
Study: 3092699
Drug: 0.75‐1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75‐1.0 mg/kg tramadol
Study: 8679352
Drug: Remifentanil low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil low dose (1 microgram kg‐1 i.v. over 1 min and an infusion of 0.2 microgram kg‐1 min‐1)
Study: 8679352
Drug: Remifentanil medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil medium dose (2.5 micrograms kg‐1 and 0.5 microgram kg‐1 min‐1)
Study: 8679352
Drug: Remifentanil high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil high dose (5 micrograms kg‐1 and 1 microgram kg‐1 min‐1)
Study: 12635062
Drug: Remifentanil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (all doses)
Study: 2056600
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (75 mg.) BCG regimen
Study: 6192650
Drug: H1 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 and H2 receptor antagonists (used separately and in combination)
Study: 6192650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H1 plus H2 antagonist
Study: 29149805
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists
Study: 6192650
Drug: Potent H1
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent H1 blocker alone
Study: 29715698
Drug: ETX +
Normalized name: Polygonatum biflorum root etxract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETX + 1,25‐(OH) 2 D 3 (1 ng/mL)
Study: 29715698
Drug: 1,25‐(OH) 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25‐(OH) 2 D 3 (1 ng/mL)
Study: 26813210
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch only (n=241)
Study: 26813210
Drug: Combination nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination nicotine replacement therapy (C‐NRT) (n=421)
Study: 22684521
Drug: HPV16 synthetic
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 synthetic long-peptide vaccine (1-2 vaccinations)
Study: 20711437
Drug: Multisensory exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory exercises (GMS), twice a week for 12 weeks
Study: 20711437
Drug: Strength exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength exercises (GST), twice a week for 12 weeks
Study: 17940245
Drug: Diazepam infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam infusion
Study: 17198918
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 1.5 mg
Study: 10628626
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg)
Study: 8953340
Drug: Oral vanadyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vanadyl sulfate (VOSO4) 0.5 mg/kg/day
Study: 8953340
Drug: Oral vanadyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vanadyl sulfate (VOSO4)
Study: 6812154
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO2 mixture
Study: 6812154
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of air (placebo control)
Study: 29143550
Drug: Inebilizumab (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inebilizumab (IV doses: 30, 100, or 600 mg; SC doses: 60 or 300 mg)
Study: 29143550
Drug: Inebilizumab (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inebilizumab (IV doses)
Study: 29143550
Drug: Inebilizumab (SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inebilizumab (SC doses)
Study: 21094099
Drug: Lignocaine gel-soaked
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine gel-soaked Falope rings
Study: 21094099
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac suppository
Study: 21094099
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic
Study: 9260731
Drug: Sabeluzole 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabeluzole 5 mg twice daily
Study: 9260731
Drug: Sabeluzole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabeluzole 10 mg twice daily
Study: 9260731
Drug: Sabeluzole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabeluzole (5 or 10 mg)
Study: 1437338
Drug: Exosurf (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (3 doses)
Study: 1437338
Drug: Exosurf (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (2 doses)
Study: 1437338
Drug: Exosurf (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (1 dose)
Study: 3873877
Drug: Betamethasone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (50 micrograms, total 300 micrograms) administered intradermally (i.d.) over 10 days
Study: 3873877
Drug: Single i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.d. injection of 50 micrograms betamethasone 24 hours prior to anti-IgE challenge
Study: 3873877
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of betamethasone 2 hours prior to and together with anti-IgE
Study: 3873877
Drug: Betamethasone administered
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone administered i.d. 30 minutes following anti-IgE challenge